Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) FCF Margin (2016 - 2025)

Historic FCF Margin for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to 400.48%.

  • Coherus Oncology's FCF Margin rose 6242400.0% to 400.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 139.88%, marking a year-over-year decrease of 106000.0%. This contributed to the annual value of 7.66% for FY2024, which is 604400.0% up from last year.
  • Latest data reveals that Coherus Oncology reported FCF Margin of 400.48% as of Q3 2025, which was up 6242400.0% from 4259.49% recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's FCF Margin registered a high of 6111.66% during Q1 2024, and its lowest value of 1024.72% during Q3 2024.
  • For the 5-year period, Coherus Oncology's FCF Margin averaged around 453.93%, with its median value being 71.97% (2021).
  • Per our database at Business Quant, Coherus Oncology's FCF Margin surged by 63240200bps in 2024 and then crashed by -65136200bps in 2025.
  • Coherus Oncology's FCF Margin (Quarter) stood at 71.97% in 2021, then plummeted by -207bps to 220.59% in 2022, then surged by 94bps to 14.17% in 2023, then skyrocketed by 181bps to 11.52% in 2024, then tumbled by -3576bps to 400.48% in 2025.
  • Its last three reported values are 400.48% in Q3 2025, 4259.49% for Q2 2025, and 401.96% during Q1 2025.